Revolutionizing Cancer Treatment with Ligufalimab
Akeso Inc. (9926.HK) has recently achieved a significant milestone with its humanized IgG4 monoclonal antibody, ligufalimab (AK117), attaining Orphan Drug Designation (ODD) from the U.S. FDA. This designation specifically targets treatment for acute myeloid leukemia (AML), a serious and often aggressive form of cancer.
Understanding Orphan Drug Designation
The Orphan Drug Designation program by the FDA aims to encourage the development of drugs for rare diseases. By offering valuable benefits like regulatory support, tax incentives, and an extended market exclusivity period of up to seven years post-approval, the initiative notably incentivizes pharmaceutical companies to invest in developing treatments that would otherwise lack adequate commercial interest.
Akeso's Dynamic Approach to Development
Akeso is advancing ligufalimab through various international clinical trials not just for AML but also for other hematologic malignancies and solid tumors. Patient enrollment in a Phase II trial is already completed, focusing on the application of ligufalimab combined with azacitidine for patients with high-risk myelodysplastic syndromes (HR-MDS).
Ligufalimab in Phase III Trials
Notably, ligufalimab is the first CD47 monoclonal antibody to commence registrational Phase III trials for solid tumors. Currently, two pivotal studies are investigating its effectiveness in combination with ivonescimab as a frontline therapy for patients with PD-L1-positive head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer.
Insight into Acute Myeloid Leukemia
Acute myeloid leukemia is a complex hematologic condition that features the clonal expansion of myeloid blasts in various body compartments. It stands as the predominant type of acute leukemia affecting adults. Treatment strategies for AML often depend on the patient's eligibility for intensive induction chemotherapy, with limited options available for those who aren't candidates.
Current Standard Treatments and Their Limitations
As of now, the FDA has approved venetoclax in conjunction with either azacitidine, decitabine, or low-dose cytarabine for newly diagnosed AML patients aged 75 or older or those unable to undergo intensive chemotherapy. Unfortunately, over 50% of these patients experience relapses within 6 to 9 months, resulting in a median overall survival of about one year—indicating a pressing need for alternative therapeutic options.
Mechanism of Action of Ligufalimab
Ligufalimab functions as a humanized IgG4 monoclonal antibody that specifically binds to CD47 on tumor cells, thereby blocking its interaction with the SIRP? receptor. This action disrupts the protective "don't eat me" signal, which enhances the immune system's ability to destroy tumor cells via macrophage-mediated phagocytosis. Additionally, ligufalimab has been designed to mitigate red blood cell agglutination, showcasing superior safety and efficacy compared to rival CD47-targeting treatments.
Promising Findings from Clinical Trials
Preliminary findings reveal that ligufalimab, when administered with azacitidine or venetoclax, boosts the expression of “eat me” signals like calreticulin, leading to enhanced phagocytic immune responses. Clinical trials have illustrated that the combination of ligufalimab and azacitidine offers a favorable safety profile while demonstrating promising effectiveness in treating AML.
In fact, at higher doses (up to 45 mg/kg on a biweekly schedule), ligufalimab has shown an impressive 50% complete remission (CR) rate alongside a composite complete remission (cCR) rate of 55%. Buoyed by these findings, Akeso is embarking on another Phase II trial to further evaluate ligufalimab in combination with venetoclax and azacitidine for AML patients who cannot undergo standard intensive chemotherapy.
About Akeso and Future Prospects
Founded in 2012, Akeso (HKEX: 9926.HK) is a prominent biopharmaceutical company that focuses on researching, developing, manufacturing, and commercializing innovative biological medications. Akeso has established a comprehensive suite of capabilities, including the ACE Platform for end-to-end drug development and Tetrabody for bispecific antibody production, enabling it to maintain a robust pipeline of over 50 innovative assets targeting major diseases such as cancer, autoimmune disorders, and inflammation.
Frequently Asked Questions
What is ligufalimab and why is it important?
Ligufalimab is a humanized IgG4 monoclonal antibody targeting CD47, recently granted Orphan Drug Designation for AML treatment.
What benefits come with Orphan Drug Designation?
This designation provides incentives like regulatory support, tax benefits, and an exclusivity period to promote development for rare diseases.
What types of cancer is ligufalimab being evaluated for?
Ligufalimab is being studied for AML, myelodysplastic syndromes, and solid tumors, particularly in ongoing Phase III trials.
How does ligufalimab enhance treatment efficacy?
By blocking CD47, ligufalimab increases macrophage activity to phagocytize tumor cells, disrupting their protection against the immune system.
What is Akeso's commitment to innovation?
Akeso is dedicated to creating first-in-class and best-in-class therapies, aiming to provide effective and affordable options for patients globally.
